AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-15. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
== Contraindications == Circulatory collapse, depressed level of consciousness due to any cause, Coma. Severe depression requiring hospitalization or electroconvulsive therapy. Not recommended for use in states of excitement or overactivity.
10 December: The Taranaki Regional Council confirms that Lake Rotomanu in New Plymouth will be drained over the next four days commencing 11 December in response to a Corbicula fluminea infestation. The Court of Appeal of New Zealand overturns a 2023 High Court ruling finding that toy company Zuru's packaging had infringed on Lego's trademark. The New Zealand Government launches a new mobile app called "Govt.nz" to make it easier for people to access government services. 11 December: The New Zealand Parliament passes two urgent laws delaying a ban on farrowing crates by ten years and legislation amending the Fast-track Approvals Act 2024. Parliament rejects a 36,549-strong petition organised by Queenstown Volunteer Fire Brigade secretary Katherine Lamont for volunteer firefighters to receive the same ACC coverage as professional firefighters. Principals affiliated with the New Zealand Educational Institute reject a 4.6 percent government pay offer, citing the exclusion of a curriculum change allowance. 12 December: The Christchurch District Court fines three companies Skyline Enterprises, Naylor Love Central Otago Limited and Wilsons Contractors Limited over a total of NZ$500,000 for their role in a landslide that damaged a Queenstown street during the 2023 southern New Zealand floods. The three companies also pleaded guilty to breaching the Resource Management Act 1991. Former Gloriavale Christian Community leader Howard Temple is sentenced to 26 months in jail for indecently assaulting girls and women over a 20 year period.
=== Chiral crown ether === Chiral crown stationary phases consist Crown ethers, immobilized or bonded to the support particles, are polyethers with a macrocyclic structure that can create host-guest complexes with alkali, earth-alkali metal ions, and ammonium cations. The skeleton of the cyclic structure is composed of oxygen and methylene groups arranged alternately. The electron-donating ether oxygens are positioned within the inner wall of the crown cavity, and are encircled by methylene groups in a collar-like arrangement. The chiral recognition is based on two distinct diastereomeric inclusion complexes that can be generated. The primary interactions facilitating complexation involve hydrogen bonds, formed between the three amine hydrogens and the oxygens of the macrocyclic ether, arranged in a tripod configuration. Additionally, ionic interactions, dipole-dipole interactions, or hydrogen bonds can occur between the carbocyclic groups and polar groups of the analytes, providing further support for the complexes.
== Radiation protection in radiotherapy == In radiotherapy, radiation protection is often overlooked in favor of structural safeguards and therapist protection. The benefit/risk assessment should prioritize both the therapeutic goal of treating the patient's cancer and the safety of all involved. However, it is crucial to ensure that radiation is delivered only where it is needed through appropriate treatment planning. By employing strong radiation protection measures, we can confidently provide effective treatment while minimizing potential risks. Linear accelerators replaced cobalt and caesium emitters in routine therapy due to their superior technical characteristics and risk profile. They have been available since about 1970. The presence of a medical physicist responsible for technical quality control is required for linear accelerators, unlike X-rays and telecurie systems. It is important to note that radiation necrosis is the necrosis of cells in an organism caused by the effects of ionizing radiation. Radionecrosis is a serious complication of radiosurgical treatment that becomes clinically apparent months or years after irradiation. Radiation therapy has significantly reduced the incidence of radionecrosis since its early days. Modern radiation techniques prioritize the sparing of healthy tissue while irradiating as much of the area around the tumor as possible to prevent recurrence. It is important to note that patients undergoing radiotherapy face a certain level of radiation risk.
Sources: en.wikipedia.org
== Side effects == Clinical studies have found that deramciclane is well-tolerated in humans at dosages ranging between 0.2–150 mg. All reported side effects were mild-moderate with the most common side effect being headache and dizziness. No severe side effects were reported in any clinical trial, and no side effects were found to be dose-dependent. Trial participants showed no significant increases in liver enzyme activity and no changes in ECGs, systolic blood pressure, diastolic blood pressure, HDL cholesterol, or LDL cholesterol levels. Another advantage to deramciclane is that it did not produce any withdrawal effects after long-term studies, like other anxiolytics do.
== Human adverse effects == After the bite, almost no pain will be felt at the bite site. However, after a (short) while, speech may slur, swallowing will become more difficult and the person might feel dizzy. Somewhat later, the weakness can spread from the face region to the limbs, and muscles may become slightly paralyzed. Respiratory failure, such as shortness of breath, can happen as well in this stage. After 6-30 hours of the envenomation, victims may be unable to move or unable to breathe. Death can occur when cardiac arrest happens due to lack of oxygen. About 27.3% of the patients in Taiwan experienced either general pain symptoms or respiratory failure. There is specific antivenom available in Taiwan but this may not effectively prevent respiratory failure and pain. Patients must be closely monitored within the first few hours of envenomation for signs of paralysis and respiratory distress.
Sublimation is the transition of a substance directly from the solid to the gas state, without passing through the intermediate liquid state. The verb form of sublimation is sublime, or less preferably, sublimate. Sublimate also refers to the product obtained by sublimation. The point at which sublimation occurs rapidly (for definition, see below) is called critical sublimation point, or simply, sublimation point. Notable examples include sublimation of dry ice at room temperature and atmospheric pressure, and that of solid iodine with heating. The reverse process of sublimation is deposition (also called desublimation), in which a substance passes directly from a gas to a solid phase, without passing through the intermediate liquid state. Technically, all solids may sublime, though most sublime at extremely low rates that are hardly detectable under usual conditions. At normal pressures, most chemical compounds and elements possess three different states at different temperatures. In these cases, the transition from the solid to the gas state requires an intermediate liquid state. The pressure referred to is the partial pressure of the substance, not the total (e.g. atmospheric) pressure of the entire system. Thus, any solid can sublime if its vapour pressure is higher than the surrounding partial pressure of the same substance, and in some cases, sublimation occurs at an appreciable rate (e.g. water ice just below 0 °C).
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.